---
title: "GSK to buy Canada's 35Pharma for $950 million"
description: "GSK has agreed to acquire Canadian biopharmaceutical company 35Pharma for $950 million. This acquisition, aimed at enhancing GSK's respiratory portfolio, includes 35Pharma's drug for pulmonary hyperte"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/276848775.md"
published_at: "2026-02-25T07:27:48.000Z"
---

# GSK to buy Canada's 35Pharma for $950 million

> GSK has agreed to acquire Canadian biopharmaceutical company 35Pharma for $950 million. This acquisition, aimed at enhancing GSK's respiratory portfolio, includes 35Pharma's drug for pulmonary hypertension. This marks GSK's second major acquisition under CEO Luke Miels, following a $2.2 billion deal for RAPT Therapeutics in January. Additionally, GSK recently secured a $1 billion deal for rights to develop two RNA therapies for kidney diseases.

Feb 25 (Reuters) - GSK (GSK.L) on Wednesday agreed to pay $950 million in cash for Canadian biopharmaceutical company 35Pharma Inc, which is developing a medicine for pulmonary hypertension.

The deal marks GSK’s second major acquisition under new CEO Luke Miels, after it agreed to buy RAPT Therapeutics (RAPT.O) for $2.2 billion in January.

GSK will acquire 35Pharma’s in-development drug to treat pulmonary hypertension, a life-shortening disease marked by high blood pressure in the lungs, helping the company expand its respiratory portfolio.

The British drugmaker earlier this week agreed to a $1 billion deal to acquire global rights to develop Frontier Biotechnologies’ (688221.SS) two small interfering RNA therapies targeting kidney diseases.

### Related Stocks

- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [RAPT.US - RAPT Therapeutics](https://longbridge.com/en/quote/RAPT.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| A Look At Avidity Biosciences (RNA) Valuation After Strong Multi Year Shareholder Returns | Avidity Biosciences (RNA) has shown a total shareholder return of 145.53% over the past year, despite a significant net  | [Link](https://longbridge.com/en/news/276982130.md) |
| Why Is Avidity Biosciences Stock (RNA) Down Today? | Avidity Biosciences (RNA) stock fell after shareholders approved a merger with Novartis (NVS), which includes spinning o | [Link](https://longbridge.com/en/news/277213257.md) |
| REG - GSK PLC - Director/PDMR Shareholding | GSK plc announced that Maya Martinez-Davis, President of the US, acquired American Depositary Shares (ADS) as part of he | [Link](https://longbridge.com/en/news/277222111.md) |
| GSK Discloses February 20 Executive Notional ADS Acquisitions via Dividend Reinvestment | GSK disclosed that on February 20, 2026, non-executive director Dr. Hal Barron acquired 2,007.552 notional ADS through d | [Link](https://longbridge.com/en/news/276767817.md) |
| GSK Discloses Pension Plan ADS Purchase by Chief People Officer | GSK disclosed that Chief People Officer Diana Conrad purchased American Depositary Shares through a pension plan transac | [Link](https://longbridge.com/en/news/276923418.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.